keyword
MENU ▼
Read by QxMD icon Read
search

salvage prostate

keyword
https://www.readbyqxmd.com/read/28439616/-high-intensity-focused-ultrasound-hifu-importance-in-the-treatment-of-prostate-cancer
#1
R Ganzer
BACKGROUND: High intensity focused ultrasound (HIFU) has been used since the beginning of the 1990s as an alternative treatment for prostate cancer. OBJECTIVE: Overview of the current status and critical review of the different indications for HIFU in the treatment of prostate cancer. MATERIAL AND METHODS: Review of the current literature on the indications, side effects, oncologic results and current guideline recommendations. RESULTS: The principle of HIFU is based on high energy sound waves, which lead to coagulation necrosis at the focal point...
April 24, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28437170/psa-nadir-of-0-1-or-less-is-a-predictor-of-treatment-success-in-men-undergoing-salvage-whole-prostate-gland-cryoablation
#2
Yaw A Nyame, Ahmad Elshafei, Daniel Greene, Hans C Arora, Robert W Given, Kae Jack Tay, Thomas J Polascik, Ashley Ross, Vladimir Mouraviev, Franco Lugnani, J Stephen Jones
PURPOSE: To assess factors that affect prostate biopsy results following salvage whole gland cryoablation Patients and Methods: 174 patients underwent prostate biopsy following salvage whole gland cryoablation of the prostate in the Cryo OnLine Database registry. Wilcoxon rank-sum, χ2 tests, and logistic regression analysis were used to assess predictors of positive biopsy. PSA nadir was divided into a statistical tertile for comparisons between different nadir PSA cutpoints. RESULTS: 52/174 (29...
February 11, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28434181/management-options-for-biochemically-recurrent-prostate-cancer
#3
REVIEW
Farhad Fakhrejahani, Ravi A Madan, William L Dahut
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent...
May 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28433640/partial-gland-treatment-of-prostate-cancer-utilizing-high-intensity-focused-ultrasound-in-the-primary-and-salvage-setting-a-systematic-review
#4
REVIEW
Ron Golan, Adrien N Bernstein, Timothy D McClure, Art Sedrakyan, Neal A Patel, Dipen J Parekh, Leonard S Marks, Jim C Hu
PURPOSE: Advances in prostate imaging, biopsy and ablative technologies have been accompanied by growing enthusiasm for partial gland ablation, particularly using high-intensity focused ultrasound (HIFU) for treating prostate cancer. The preservation of non-cancerous prostate tissue and minimizing damage to the neurovascular bundles and external urethral sphincter may improve functional outcomes. MATERIALS AND METHODS: A systematic review was performed following the PRISMA guidelines using a combination of MeSH terms, free-text search, and review of relevant bibliographies using Medline and Embase from the inception of each database through October 10, 2016...
April 19, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28422584/pre-and-post-prostatectomy-variables-associated-with-pelvic-post-operative-radiotherapy-in-prostate-cancer-patients-a-national-registry-based-study
#5
Kari Vatne, Andreas Stensvold, Tor Å Myklebust, Bjørn Møller, Aud Svindland, Rune Kvåle, Sophie D Fosså
BACKGROUND: In patients with prostate cancer (PCa), the lack of clear guidelines on the use of radiotherapy after radical prostatectomy (RP) invites unwanted variation of this treatment. We describe the hazard ratios and probabilities related to the use of post-RP radiotherapy. MATERIAL AND METHODS: Data were collected from the Cancer Registry of Norway and nine radiotherapy units. All patients were diagnosed with a non-metastatic PCa from January 2004 through June 2011...
April 19, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28422278/decipher-test-impacts-decision-making-among-patients-considering-adjuvant-and-salvage-treatment-after-radical-prostatectomy-interim-results-from-the-multicenter-prospective-pro-impact-study
#6
John L Gore, Marguerite du Plessis, María Santiago-Jiménez, Kasra Yousefi, Darby J S Thompson, Lawrence Karsh, Brian R Lane, Michael Franks, David Y T Chen, Mark Bandyk, Fernando J Bianco, Gordon Brown, William Clark, Adam S Kibel, Hyung L Kim, William Lowrance, Murugesan Manoharan, Paul Maroni, Scott Perrapato, Paul Sieber, Edouard J Trabulsi, Robert Waterhouse, Elai Davicioni, Yair Lotan, Daniel W Lin
BACKGROUND: Patients with prostate cancer and their providers face uncertainty as they consider adjuvant radiotherapy (ART) or salvage radiotherapy (SRT) after undergoing radical prostatectomy. The authors prospectively evaluated the impact of the Decipher test, which predicts metastasis risk after radical prostatectomy, on decision making for ART and SRT. METHODS: A total of 150 patients who were considering ART and 115 who were considering SRT were enrolled. Providers submitted a management recommendation before processing the Decipher test and again at the time of receipt of the test results...
April 19, 2017: Cancer
https://www.readbyqxmd.com/read/28417160/diagnosis-of-recurrent-prostate-cancer-with-pet-ct-imaging-using-the-gastrin-releasing-peptide-receptor-antagonist-68-ga-rm2-preliminary-results-in-patients-with-negative-or-inconclusive-18-f-fluoroethylcholine-pet-ct
#7
Gesche Wieser, Ilinca Popp, H Christian Rischke, Vanessa Drendel, Anca-Ligia Grosu, Mark Bartholomä, Wolfgang A Weber, Rosalba Mansi, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer, Cordula Annette Jilg
PURPOSE/BACKGROUND: [(18)F]fluoroethylcholine ((18)FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the (68)Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive (18)FECH-PET/CT...
April 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28409355/percutaneous-mr-guided-focal-cryoablation-for-recurrent-prostate-cancer-following-radiation-therapy-retrospective-analysis-of-iceball-margins-and-outcomes
#8
Christiaan G Overduin, Sjoerd F M Jenniskens, J P Michiel Sedelaar, Joyce G R Bomers, Jurgen J Fütterer
OBJECTIVES: To evaluate iceball margins after magnetic resonance (MR)-guided focal salvage prostate cryoablation and determine the correlation with local outcome. METHODS: A retrospective review was performed on 47 patients that underwent percutaneous MR-guided focal cryoablation for biopsy-proven locally recurrent prostate cancer after primary radiotherapy. Preprocedural diagnostic and intraprocedural MR images were analysed to derive three-directional iceball margins...
April 13, 2017: European Radiology
https://www.readbyqxmd.com/read/28408529/targeted-alpha-therapy-of-mcrpc-with-225-actinium-psma-617-dosimetry-estimate-and-empirical-dose-finding
#9
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederick Lars Giesel, Alfred Morgenstern
To develop a treatment protocol for (225)Ac-PSMA-617 alpha-radiation therapy in advanced stage, metastatic castration-resistant prostate cancer patients with PSMA-positive tumor phenotype. Methods: A dosimetry estimate was calculated based on time-activity-curves derived from serially performed (177)Lu-PSMA-617 scans extrapolated to the physical half-life of (225)Ac, assuming instant decay of instable daughter nuclides. Salvage therapies empirically conducted with 50kBq/kg (n = 4), 100kBq/kg (n = 4), 150kBq/kg (n = 2), 200kBq/kg (n = 4) (225)Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28396727/multimodality-imaging-using-proton-magnetic-resonance-spectroscopic-imaging-and-18-f-fluorodeoxyglucose-positron-emission-tomography-in-local-prostate-cancer
#10
Amita Shukla-Dave, Cecilia Wassberg, Darko Pucar, Heiko Schöder, Debra A Goldman, Yousef Mazaheri, Victor E Reuter, James Eastham, Peter T Scardino, Hedvig Hricak
AIM: To assess the relationship using multimodality imaging between intermediary citrate/choline metabolism as seen on proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and glycolysis as observed on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in prostate cancer (PCa) patients. METHODS: The study included 22 patients with local PCa who were referred for endorectal magnetic resonance imaging/(1)H-MRSI (April 2002 to July 2007) and (18)F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment...
March 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28396223/oncological-and-functional-results-of-robotic-salvage-radical-prostatectomy-after-permanent-brachytherapy-implants
#11
M Orré, T Piéchaud, P Sargos, P Richaud, G Roubaud, L Thomas
PURPOSE: To evaluate the feasibility of robotic salvage prostatectomy for local recurrence after permanent brachytherapy implants for prostate cancer. PATIENTS AND METHODS: Seven patients were operated by robotic salvage prostatectomy with or without pelvic lymph node dissection between October 2007 and March 2012, for a local recurrence after iodine 125 permanent brachytherapy implants. Local recurrence was proved by prostate biopsies, once biochemical relapse was diagnosed and imaging assessment performed...
April 7, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28379660/quality-of-life-after-post-prostatectomy-intensity-modulated-radiation-therapy-to-the-prostate-bed-with-or-without-the-use-of-gold-fiducial-markers-for-image-guidance-or-higher-total-radiotherapy-doses
#12
Yazan A Abuodeh, Arash O Naghavi, Tzu-Hua Juan, Zhenjun Ma, Richard B Wilder
PURPOSE: To evaluate quality of life (QoL) after post-prostatectomy intensity modulated radiation therapy (IMRT) in the "adjuvant" setting starting within 4 months of radical prostatectomy for adverse features; and "salvage" setting for a PSA≥0.2ng/mL. MATERIALS AND METHODS: Retrospective review of 130 patients who underwent IMRT to the prostate bed±gold fiducial marker placement for image guidance to 64.8-72.0Gy (median, 70.2Gy) between 2004 and 2013. Higher doses were defined as 70...
April 6, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28373480/salvage-robotic-assisted-laparoscopic-radical-prostatectomy-experience-with-14-cases
#13
Yen-Chuan Ou, Sheng-Chun Hung, Li-Hua Hwang, Chun-Kuang Yang, Siu-Wan Hung, Min-Che Tung
AIM: To report the outcomes of salvage robot-assisted radical prostatectomy (S-RaRP). PATIENTS AND METHODS: Fourteen patients underwent S-RaRP. The mean initial prostatic-specific antigen level was 14.3 ng/ml and mean Gleason score was 6.93. Initial definitive treatment was external irradiation in 11 cases, cyberknife in two, and high-intensity focused ultrasound in one. Time from definitive treatment to S-RaRP was a mean of 36.5 months. RESULTS: The mean console time was 134...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28355119/high-intensity-focused-ultrasound-for-the-treatment-of-prostate-cancer-a-review
#14
Christian G Chaussy, Stefan Thüroff
Over the past 25 years, the average life expectancy for men has increased almost 4 years, and the age of prostate cancer detection has decreased an average of 10 years with diagnosis increasingly made at early-stage disease where curative therapy is possible. These changing trends in the age and extent of malignancy at diagnosis have revealed limitations in conventional curative therapies for prostate cancer, including a significant risk of aggressive cancer recurrence, and the risk of long-term genitourinary morbidity and its detrimental impact on patient's quality of life (QOL)...
April 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28346770/a-core-outcome-set-for-localised-prostate-cancer-effectiveness-trials
#15
Steven MacLennan, Paula R Williamson, Hanneke Bekema, Marion Campbell, Craig Ramsay, James N'Dow, Sara MacLennan, Luke Vale, Philipp Dahm, Nicolas Mottet, Thomas Lam, Paul Abel, Hashim U Ahmed, Gary Akehurst, Robert Almquist, Karl Beck, David Budd, Steven Canfield, James Catto, Philip Cornford, William Cross, Alexander Ewen, Judith Grant, Rakesh Heer, David Hurst, Rob Jones, Roger Kockelbergh, Andrew Mackie, Graham MacDonald, Alan McNeill, Malcolm Mason, Sam McClinton, Duncan McLaren, Hugh Mostafid, Ian Pearce, Linda Pennet, Justine Royle, Hans Schreuder, Grant D Stewart, Henk van der Poel, Kevin Wardlaw, Thomas Wiegel
OBJECTIVE: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. BACKGROUND: Many treatments exist for localised prostate cancer, although it is unclear which offers the optimal therapeutic ratio. This is confounded by inconsistencies in the selection, definition, measurement and reporting of outcomes in clinical trials. SUBJECTS AND METHODS: A list of 79 outcomes was derived from a systematic review of published localised prostate cancer effectiveness studies and semi-structured interviews with 15 prostate cancer patients...
March 27, 2017: BJU International
https://www.readbyqxmd.com/read/28342996/induction-of-neuroendocrine-differentiation-in-prostate-cancer-cells-by-dovitinib-tki-258-and-its-therapeutic-implications
#16
Shalini S Yadav, Jinyi Li, Jennifer A Stockert, Bryan Herzog, James O'Connor, Luis Garzon-Manco, Ramon Parsons, Ashutosh K Tewari, Kamlesh K Yadav
Prostate cancer (PCa) remains the second-leading cause of cancer-related deaths in American men with an estimated mortality of more than 26,000 in 2016 alone. Aggressive and metastatic tumors are treated with androgen deprivation therapies (ADT); however, the tumors acquire resistance and develop into lethal castration resistant prostate cancer (CRPC). With the advent of better therapeutics, the incidences of a more aggressive neuroendocrine prostate cancer (NEPC) variant continue to emerge. Although de novo occurrences of NEPC are rare, more than 25% of the therapy-resistant patients on highly potent new-generation anti-androgen therapies end up with NEPC...
March 24, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28341011/interstitial-high-dose-rate-brachytherapy-as-salvage-treatment-for-locally-recurrent-prostate-cancer-after-definitive-radiation-therapy-toxicity-and-5-year-outcome
#17
Ping Jiang, Christof van der Horst, Bernhard Kimmig, Fabian Zinsser, Bjoern Poppe, Ulf Luetzen, Klaus-Peter Juenemann, Juergen Dunst, Frank-André Siebert
PURPOSE: We report our results with interstitial high-dose-rate brachytherapy (HDR-BT) as a salvage therapy option after external beam therapy with or without BT. Emphasis was put on toxicity and 5-year outcome. METHODS AND MATERIALS: From 2003 to 2011, 29 patients with local failure after previous radiotherapy for prostate cancer were treated with salvage interstitial HDR-BT. The diagnosis of local recurrence was made on the basis of choline positron emission tomography...
January 2017: Brachytherapy
https://www.readbyqxmd.com/read/28333020/-18-f-choline-positron-emission-tomography-computed-tomography-and-multiparametric-magnetic-resonance-imaging-for-the-detection-of-early-local-recurrence-of-prostate-cancer-initially-treated-by-radiation-therapy-comparison-with-systematic-3-dimensional-transperineal
#18
Salim Kanoun, Paul Walker, Jean-Marc Vrigneaud, Edouard Depardon, Vincent Barbier, Olivier Humbert, Morgan Moulin, Gilles Créhange, Luc Cormier, Romaric Loffroy, François Brunotte, Alexandre Cochet
PURPOSE: To compare the diagnostic performance of (18)F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT), multiparametric prostate magnetic resonance imaging (mpMRI), and a combination of both techniques for the detection of local recurrence of prostate cancer initially treated by radiation therapy. METHODS AND MATERIALS: This was a retrospective, single-institution study of 32 patients with suspected prostate cancer recurrence who underwent both FCH-PET/CT and 3T mpMRI within 3 months of one another for the detection of recurrence...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333019/a-comparison-between-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-external-beam-radiation-therapy-with-or-without-androgen-deprivation-and-radical-prostatectomy-with-or-without-adjuvant-or-salvage-radiation-therapy-for-high-risk-prostate
#19
Jay P Ciezki, Michael Weller, Chandana A Reddy, Jeffrey Kittel, Harguneet Singh, Rahul Tendulkar, Kevin L Stephans, James Ulchaker, Kenneth Angermeier, Andrew Stephenson, Steven Campbell, Georges-Pascal Haber, Eric A Klein
PURPOSE: We compare the efficacy and toxicity among the 3 major modalities available used to treat high-risk prostate cancer (HRCaP). METHODS AND MATERIALS: From 1996 to 2012, 2557 HRCaP patients were treated: 734 received external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), 515 received low-dose-rate prostate brachytherapy (LDR) with or without ADT, and 1308 received radical prostatectomy (RP) with or without EBRT. Biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and prostate cancer-specific mortality (PCSM) were assessed...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28317152/-68-ga-psma-pet-for-radiation-treatment-planning-in-prostate-cancer-recurrences-after-surgery-individualized-medicine-or-new-standard-in-salvage-treatment
#20
Gregor Habl, Katharina Sauter, Kilian Schiller, Sabrina Dewes, Tobias Maurer, Matthias Eiber, Stephanie E Combs
BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP± prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department...
June 2017: Prostate
keyword
keyword
98726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"